Evidence map›Paper›PMID 34570949›Full record

ArticlePediatric pulmonology2022

Feasibility of nasal NO screening in healthy newborns.

Flurina Buechel, Jakob Usemann, A Aline, Peter Salfeld, Alexander Moeller, Andreas Jung

Open access · hybridAbstract read
In one paragraph

Article in Pediatric pulmonology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Flurina BuechelDivision of Respiratory Medicine & Children's Research Centre, University Children's Hospital Zurich.
Jakob UsemannDivision of Respiratory Medicine & Children's Research Centre, University Children's Hospital Zurich.ORCID 0000-0002-9987-2866
A AlineDivision of Respiratory Medicine & Children's Research Centre, University Children's Hospital Zurich.
Peter SalfeldKantonsspital Muensterlingen, Münsterlingen, Switzerland.
Alexander MoellerDivision of Respiratory Medicine & Children's Research Centre, University Children's Hospital Zurich.ORCID 0000-0001-7284-4251
Andreas JungDivision of Respiratory Medicine & Children's Research Centre, University Children's Hospital Zurich.ORCID 0000-0002-3505-6691
University Children's Hospital Zurich · CHKantonsspital Münsterlingen · CHUniversity Children’s Hospital Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNasal nitric oxide (nNO) measurement is recommended as a first line screening test for primary ciliary dyskinesia (PCD). While reliable velum- and non-velum-closure techniques exist for preschool children and older individuals, no data are available for neonates.

aimsTo determine feasibility of nNO screening and nNO concentration in healthy newborns in the first week of life.

methodsNasal NO was analyzed in tidal breathing during natural sleep using a CLD-88 sp NO analyzer (chemoluminescence sensor) and a NIOX MINO (electrochemical sensor). Test success and nNO concentration were determined and compared between the two devices.

resultsNasal NO was measured in 62 healthy neonates within the first week of life. Feasibility of nNO measurement was 100% for at least one nostril and 85.5% for both nostrils using the chemoluminescence device, but significantly lower with the electrochemical device (85.5% and 53.2%; p < .001). Median nNO concentration was 38 ppb (interquartile range, 27-55; range, 9-100) with the ECOMEDICS device and 23 (15-33, 8-59) with the NIOX MINO (p < .001), with a trend towards higher values for older subjects. None of the subjects exceeded nNO levels of 100 ppb.

conclusionMeasurement of nNO using a chemoluminescence device is highly feasible in newborns during natural sleep. However, nNO levels are considerably lower compared to the published data for older individuals and in the range of a PCD reference group of infants between 4 and 8 weeks of age, potentially resulting in a great overlap with subjects with PCD in this age group. Therefore, screening for PCD using nasal NO might not be useful in the first week of life. Upon clinical suspicion, other diagnostic tests such as high-speed video analysis of the cilia should be applied.

Indexed as

Breath TestsKartagener SyndromeChild, PreschoolFeasibility StudiesHumansInfantInfant, NewbornNitric OxideNoseNitric Oxidechemoluminescenceelectrochemical sensornasal nitric oxidenewbornsprimary ciliary dyskinesiascreening

Identifiers

PMID34570949
PMCPMC9292553
OpenAlexW3202089968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.